Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow

Launched by TATA MEMORIAL CENTRE · Jul 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat gliomas, which are common brain tumors. The goal is to use a combination of advanced imaging techniques, like MRI and PET scans, along with artificial intelligence (AI) to adjust radiation treatment based on how the tumor responds during the therapy. Instead of giving a fixed amount of radiation, doctors will modify the dose based on real-time imaging to target the tumor more precisely and reduce side effects. This study will involve 60 patients over two years at Tata Memorial Centre.

To be eligible for this trial, participants should be adults aged 18 to 70 with a confirmed diagnosis of diffuse glioma, which includes specific tumor types like glioblastoma. Participants will undergo scans before and during treatment, and their treatment plans will be adjusted based on the results. It's important to note that individuals with certain conditions, such as having multiple tumor sites or previous radiation treatment, may not be eligible. Overall, this trial aims to improve the way gliomas are treated, making therapies more effective and safer for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological diagnosis of diffuse glioma. Patients with IDH-negative GBM (stratum A) and IDH-mutant glioma (astrocytoma or oligodendroglioma) need radiotherapy (stratum B).
• • Age: 18-70 years. Karnofsky Performance Scale (KPS) ≥60
• Exclusion Criteria:
• • Multifocal or multicentric disease Not eligible for radical intent radiation. IDH status is unknown or uninterpretable (IHC or gene sequencing). Use of prior radiotherapy to the head-neck region or brain or chemotherapy. Contraindication/unable to undergo MRI or PET scan during radiation.